exhibit 10. 36 license agreement between conrad, eastern virginia medical school and biosyn, inc., a subsidiary of cellegy pharmaceuticals, inc. this agreement ( this “ agreement ” ), effective as of the 30th day of january, 2006 by and between biosyn, inc. ( “ biosyn ” ), a corporation organized and existing under the laws of the commonwealth of pennsylvania and a wholly owned subsidiary of cellegy pharmaceuticals, inc. ( “ cellegy ” ), and having its principal place of business at1800 byberry road, building 13, huntingdon valley, pa 19006, and conrad, eastern virginia medical school, ( “ conrad ” ), organized and existing under the laws of the state of virginia and having its principal place of business at the address set forth in section 10. 1. witnesseth : whereas, biosyn owns or controls certain united states patents and patent applications and corresponding foreign patents and patent applications and related technology relating to compounds and formulations having microbicidal properties for treating or preventing the contraction of sexually transmitted diseases and / or inactivating pathogenic microbes ; whereas, biosyn wishes to grant to conrad a non - exclusive license to its technology related to such compounds and formulations ( as specifically defined herein ) in the developing countries to make, have made, use, research, develop, market and sell, but only for the public sector ; and whereas, conrad wishes to conduct research and development activities with regard to biosyn ’ s technology and to make, have made, use, research, develop, market and sell, in and for the benefit of the developing countries and for the public sector, products that incorporate the technology and to share the results of such research and development activities with biosyn. now, therefore, in consideration of the mutual covenants and agreements of the parties contained herein, and intending to be legally bound, the parties agree as follows : 1. definitions 1. 1. definitions “ c31g ” means compounds, compositions and processes covered under the c31g patents in schedule ii, along with associated trademarks and know - how, sometimes referred to as savvy, and for use in the prevention of transmission of sexually transmitted diseases including hiv and for contraception. “ c31g permitted field of use ” means for the prevention of infection by hiv and other sexually transmitted pathogens and for contraception, by topical, but not systemic, administration.